Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amicus Therapeutics (FOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,121,941
  • Shares Outstanding, K 189,290
  • Annual Sales, $ 36,930 K
  • Annual Income, $ -284,000 K
  • 36-Month Beta 1.77
  • Price/Sales 28.05
  • Price/Cash Flow N/A
  • Price/Book 5.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.28
  • Number of Estimates 5
  • High Estimate -0.25
  • Low Estimate -0.30
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +31.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.30 +10.87%
on 01/24/19
12.49 -8.57%
on 01/18/19
-0.57 (-4.75%)
since 01/15/19
3-Month
8.27 +38.09%
on 12/24/18
12.49 -8.57%
on 01/18/19
+1.02 (+9.81%)
since 11/15/18
52-Week
8.27 +38.09%
on 12/24/18
17.62 -35.19%
on 06/20/18
-4.41 (-27.86%)
since 02/15/18

Most Recent Stories

More News
New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD),...

FOLD : 11.42 (+1.87%)
YRCW : 7.28 (+0.83%)
BAS : 5.07 (+0.80%)
FRTA : 5.47 (+3.40%)
SHEN : 50.04 (+2.35%)
CLVS : 25.49 (+0.08%)
Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 28, 2019 at 8:30 a.m. ET to discuss financial results for the...

FOLD : 11.42 (+1.87%)
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Amicus...

FOLD : 11.42 (+1.87%)
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and...

FOLD : 11.42 (+1.87%)
ZTS : 95.37 (+2.26%)
ACAD : 23.25 (+6.02%)
ADRO : 4.05 (+10.05%)
Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium(TM)

Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue for both ERT-Naive and ERT-Switch Patients

FOLD : 11.42 (+1.87%)
Today's Research Reports on Trending Tickers: Amicus Therapeutics and ACADIA Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb....

FOLD : 11.42 (+1.87%)
Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium(TM) 2019

Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that four oral presentations...

FOLD : 11.42 (+1.87%)
Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics

NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants...

FOLD : 11.42 (+1.87%)
Research Report Identifies FedEx, Amicus Therapeutics, National HealthCare, Allegion, Horizon Global, and PICO with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of FedEx Corporation (NYSE:FDX),...

FOLD : 11.42 (+1.87%)
PICO : 10.59 (+0.76%)
NHC : 83.88 (+0.46%)
ALLE : 91.56 (-0.13%)
FDX : 179.30 (-2.51%)
HZN : 2.16 (-3.57%)
Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance

Full-Year 2018 Galafold Revenue of ~$91M Exceeds $80M-$90M Guidance

FOLD : 11.42 (+1.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade FOLD with:

Business Summary

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in...

See More

Key Turning Points

2nd Resistance Point 12.01
1st Resistance Point 11.71
Last Price 11.42
1st Support Level 11.16
2nd Support Level 10.91

See More

52-Week High 17.62
Fibonacci 61.8% 14.05
Fibonacci 50% 12.95
Fibonacci 38.2% 11.84
Last Price 11.42
52-Week Low 8.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar